This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2005 Mar 20;23(9):1796-8.

doi: 10.1200/JCO.2005.10.963. Epub 2005 Feb 7.

Indifferently pursued or unowned drugs: who should lead where companies do not tread?

Edward A Sausville

PMID: 15699475
DOI: 10.1200/JCO.2005.10.963

Editorial

Indifferently pursued or unowned drugs: who should lead where companies do not tread?

Edward A Sausville. J Clin Oncol. 2005.

. 2005 Mar 20;23(9):1796-8.

doi: 10.1200/JCO.2005.10.963. Epub 2005 Feb 7.

Author

Edward A Sausville

PMID: 15699475
DOI: 10.1200/JCO.2005.10.963

No abstract available

PubMed Disclaimer

Comment on

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, Gonen M, O'reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK. Kortmansky J, et al. J Clin Oncol. 2005 Mar 20;23(9):1875-84. doi: 10.1200/JCO.2005.03.116. Epub 2005 Feb 7. J Clin Oncol. 2005. PMID: 15699481 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.